Physician profile
Prateek Sharma
NPI 1447353354
$47,062.65
in general payments reported to CMS, 2019-2025
19 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,932 · 2021: $2,848 · 2022: $6,373 · 2023: $5,790 · 2024: $12K · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,749 · Travel and Lodging: $1,611 · Food and Beverage: $704 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,515.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,749.00 |
| Travel and Lodging | $1,611.00 |
| Food and Beverage | $703.50 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation | $13,166.06 | 2019-2023 | |
| Olympus Corporation of The Americas | $10,485.67 | 2019-2024 | Evis Exera Lll Colonovideoscope |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $8,672.98 | 2019-2023 | Xifaxan, Xifaxan |
| Exact Sciences Corporation | $4,394.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cipla USA INC. | $4,000.00 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,897.50 | 2021 | |
| Boston Scientific Corporation | $1,761.43 | 2022 | |
| Lumendi LLC | $1,000.00 | 2019 | |
| Samsung Bioepis Co., LTD. | $900.00 | 2021 | |
| Medtronic, INC. | $306.59 | 2021-2022 | |
| Fujifilm Healthcare Americas Corporation | $147.00 | 2019 | |
| Celgene Corporation | $112.75 | 2023 | Zeposia |
| Janssen Biotech, INC. | $75.00 | 2024 | Stelara |
| Covidien LP | $72.50 | 2019 | |
| Olympus America INC. | $70.24 | 2019-2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prateek Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.